Psychopharmacology

, Volume 182, Issue 1, pp 95–103

Discriminative stimulus and reinforcing effects of p-fluoro-l-deprenyl in monkeys

  • Sevil Yasar
  • Jozsef Gaal
  • Zuzana Justinova
  • Jack Bergman
Original Investigation

Abstract

Rationale

para-Fluoro-l-deprenyl (Fludepryl), a halogenated derivative of l-deprenyl, shares structural similarities with amphetamine and may have potential as a medication for psychostimulant abuse.

Objectives

p-Fluoro-l-deprenyl was evaluated for psychomotor stimulant, discriminative stimulus, and reinforcing effects in squirrel monkeys.

Methods

One group of monkeys was trained under a ten-response fixed-ratio (FR10) schedule of stimulus termination to discriminate between methamphetamine (0.32 mg/kg, i.m.) and saline. Other monkeys were trained to self-administer i.v. cocaine under either a simple FR10 schedule or a second-order fixed-interval 5-min schedule with FR10 components.

Results

Full generalization to the methamphetamine-training stimulus was produced by an i.m. dose of 10.0 mg/kg p-fluoro-l-deprenyl. l-Deprenyl and the metabolites of p-fluoro-l-deprenyl, p-fluoro-l-amphetamine, and p-fluoro-l-methylamphetamine were more potent, producing full generalization at doses of 1.0–3.2 mg/kg. Under the FR10 schedule of drug injection, persistent self-administration behavior was maintained by i.v. cocaine injections but not by injections of vehicle or injection doses of p-fluoro-l-deprenyl up to 1.0 mg/kg. However, p-fluoro-l-deprenyl did maintain moderate levels of i.v. self-administration responding under the second-order schedule of drug injection. Peak response rates maintained by 0.1-mg/kg injections of p-fluoro-l-deprenyl were significantly greater than those associated with saline substitution, yet significantly lower than those maintained by cocaine or d-amphetamine.

Conclusions

p-Fluoro-l-deprenyl has methamphetamine-like discriminative-stimulus properties in squirrel monkeys that appear at higher doses than for its parent compound, l-deprenyl. It also appears to function as a relatively limited reinforcer of intravenous self-administration behavior in monkeys trained to self-administer i.v. cocaine.

Keywords

Amphetamine Cocaine Deprenyl Drug discrimination Methamphetamine p-Fluoro-l-deprenyl Self-administration Squirrel monkey 

References

  1. Amsterdam JD (2003) A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 64:208–214PubMedGoogle Scholar
  2. Ansari KS, Yu PH, Kruck TP, Tatton WG (1993) Rescue of axotomized immature rat facial motoneurons by R(−)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 13:4042–4053PubMedGoogle Scholar
  3. Barber AJ, Yu PH, Boulton AA (1993) Chronic effects of monoamine oxidase-B inhibitors on the behaviour of aged mice. Life Sci 53:739–747CrossRefPubMedGoogle Scholar
  4. Bartzokis G, Beckson M, Newton T, Mandelkern M, Mintz J, Foster JA, Ling W, Bridge TP (1999) Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. Neuropsychopharmacology 20:582–590CrossRefPubMedGoogle Scholar
  5. Bergman J, Yasar S, Winger G (2001) Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors. Psychopharmacology (Berl) 159:21–30CrossRefGoogle Scholar
  6. Berry MD, Juorio AV, Paterson IA (1994) Possible mechanisms of action of (−)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog Neurobiol 44:141–161CrossRefPubMedGoogle Scholar
  7. Bodkin JA, Amsterdam JD (2002) Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 159:1869–1875PubMedCrossRefGoogle Scholar
  8. Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO (1996) Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. J Nerv Ment Dis 184:295–301CrossRefPubMedGoogle Scholar
  9. Buu NT, Angers M (1987) Effects of different monoamine oxidase inhibitors on the metabolism of l-dopa in the rat brain. Biochem Pharmacol 36:1731–1735PubMedCrossRefGoogle Scholar
  10. Carrillo MC, Kanai S, Nokubo M, Kitani K (1991) (−) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48:517–521CrossRefPubMedGoogle Scholar
  11. Carrillo MC, Kanai S, Nokubo M, Ivy GO, Sato Y, Kitani K (1992) (−)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp Neurol 116:286–294CrossRefPubMedGoogle Scholar
  12. Carrillo MC, Kitani K, Kanai S, Sato Y, Miyasaka K, Ivy GO (1994) The effect of a long term (6 months) treatment with (−)deprenyl on antioxidant enzyme activities in selective brain regions in old female Fischer 344 rats. Biochem Pharmacol 47:1333–1338PubMedCrossRefGoogle Scholar
  13. Cohen G (1983) The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J Neural Transm Suppl 19:89–103PubMedGoogle Scholar
  14. Dallo J, Knoll J (1992) Effect of (−)-para-fluoro-deprenyl on survival and copulation in male rats. Acta Physiol Hung 79:125–129PubMedGoogle Scholar
  15. Di Ciano P, Everitt BJ (2003) Differential control over drug-seeking behavior by drug-associated conditioned reinforcers and discriminative stimuli predictive of drug availability. Behav Neurosci 117:952–960CrossRefPubMedGoogle Scholar
  16. Erdo F, Baranyi A, Takacs J, Aranyi P (2000) Different neurorescue profiles of selegiline and p-fluoro-selegiline in gerbils. NeuroReport 11:2597–2600PubMedCrossRefGoogle Scholar
  17. Freedman M, Rewilak D, Xerri T, Cohen S, Gordon AS, Shandling M, Logan AG (1998) l-Deprenyl in Alzheimer's disease: cognitive and behavioral effects. Neurology 50:660–668PubMedGoogle Scholar
  18. Fuller RW, Hemrick-Luecke SK (1982) Influence of ring and side chain substituents on the selectivity of amphetamine as a monoamine oxidase inhibitor. Res Commun Subst Abuse 3:159Google Scholar
  19. Fuller RW, Baker JC, Perry KW, Molloy BB (1975) Comparison of 4-chloro-, 4-bromo- and 4-fluoroamphetamine in rats: drug levels in brain and effects on brain serotonin metabolism. Neuropharmacology 14:739–746CrossRefPubMedGoogle Scholar
  20. Gelowitz DL, Paterson IA (1999) Neuronal sparing and behavioral effects of the antiapoptotic drug, (−)deprenyl, following kainic acid administration. Pharmacol Biochem Behav 62:255–262CrossRefPubMedGoogle Scholar
  21. Gibson CJ (1987) Inhibition of MAO B, but not MAO A, blocks DSP-4 toxicity on central NE neurons. Eur J Pharmacol 141:135–138CrossRefPubMedGoogle Scholar
  22. Goldberg SR (1973) Comparable behavior maintained under fixed-ratio and second-order schedules of food presentation, cocaine injection or d-amphetamine injection in the squirrel monkey. J Pharmacol Exp Ther 186:18–30PubMedGoogle Scholar
  23. Goldberg SR, Kelleher RT, Morse WH (1975) Second-order schedules of drug injection. Fed Proc 34:1771–1776PubMedGoogle Scholar
  24. Goldberg SR, Spealman RD, Kelleher RT (1979) Enhancement of drug-seeking behavior by environmental stimuli associated with cocaine or morphine injections. Neuropharmacology 18:1015–1017CrossRefPubMedGoogle Scholar
  25. Grabowski J, Shearer J, Merrill J, Negus SS (2004) Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29:1439–1464CrossRefPubMedGoogle Scholar
  26. Harvey JA, McMaster SE, Fuller RW (1977) Comparison between the neurotoxic and serotonin-depleting effects of various halogenated derivatives of amphetamine in the rat. J Pharmacol Exp Ther 202:581–589PubMedGoogle Scholar
  27. Heikkila RE, Hess A, Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224:1451–1453PubMedCrossRefGoogle Scholar
  28. Heinonen EH, Savijarvi M, Kotila M, Hajba A, Scheinin M (1993) Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. J Neural Transm Parkinson's Dis Dement Sect 5:193–202CrossRefGoogle Scholar
  29. Houtsmuller EJ, Thornton JA, Stitzer ML (2002) Effects of selegiline (l-deprenyl) during smoking and short-term abstinence. Psychopharmacology (Berl) 163:213–220CrossRefGoogle Scholar
  30. Knoll J (1988) The striatal dopamine dependency of life span in male rats. Longevity study with (−)deprenyl. Mech Ageing Dev 46:237–262CrossRefPubMedGoogle Scholar
  31. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5:393–408PubMedGoogle Scholar
  32. Knoll J, Toth V, Kummert M, Sugar J (1992) (−)deprenyl and (−)parafluorodeprenyl-treatment prevents age-related pigment changes in the substantia nigra. A TV-image analysis of neuromelanin. Mech Ageing Dev 63:157–163PubMedCrossRefGoogle Scholar
  33. Lajtha A, Sershen H, Cooper T, Hashim A, Gaal J (1996) Metabolism of (−)-deprenyl and PF-(−)-deprenyl in brain after central and peripheral administration. Neurochem Res 21:1155–1160PubMedCrossRefGoogle Scholar
  34. Lane EL, Cheetham S, Jenner P (2005) Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxytryptamine and noradrenaline receptors. J Pharmacol Exp Ther 312:1124–1131PubMedCrossRefGoogle Scholar
  35. Langston JW, Irwin I, Langston EB, Forno LS (1984) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225:1480–1482PubMedCrossRefGoogle Scholar
  36. Magyar K (1994) Behaviour of (−)-deprenyl and its analogues. J Neural Transm Suppl 41:167–175PubMedGoogle Scholar
  37. Magyar K (1997) Effect of selegiline against selective neurotoxins. Vopr Med Khim 43:504–514PubMedGoogle Scholar
  38. Magyar K, Knoll J (1975) para-Substituted amphetamines and brain serotonin. Pol J Pharmacol Pharm 27:139–143PubMedGoogle Scholar
  39. Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE (1995) Psychostimulant-like effects of p-fluoroamphetamine in the rat. Eur J Pharmacol 287:105–113PubMedCrossRefGoogle Scholar
  40. McMahon LR, Cunningham KA (2001) Role of 5-HT(2a) and 5-HT(2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors. Neuropsychopharmacology 24:319–329PubMedCrossRefGoogle Scholar
  41. Negus SS, Mello NK (2003) Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend 70:39–52PubMedCrossRefGoogle Scholar
  42. Newton TF, Kalechstein A, Beckson M, Bartzokis G, Bridge TP, Ling W (1999) Effects of selegiline pretreatment on response to experimental cocaine administration. Psychiatry Res 87:101–106CrossRefPubMedGoogle Scholar
  43. Panlilio LV, Yasar S, Nemeth-Coslett R, Katz JL, Henningfield JE, Solinas M, Heishman SJ, Schindler CW, Goldberg SR (2005) Human cocaine-seeking behavior and its control by drug-associated stimuli in the laboratory. Neuropsychopharmacology 30:433–443CrossRefPubMedGoogle Scholar
  44. Paterson IA, Barber AJ, Gelowitz DL, Voll C (1997) (−)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Neurosci Biobehav Rev 21:181–186PubMedCrossRefGoogle Scholar
  45. Ritz MC, Kuhar MJ (1989) Relationship between self-administration of amphetamine and monoamine receptors in brain: comparison with cocaine. J Pharmacol Exp Ther 248:1010–1017PubMedGoogle Scholar
  46. Salo PT, Tatton WG (1992) Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 31:394–400PubMedCrossRefGoogle Scholar
  47. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336:1216–1222PubMedCrossRefGoogle Scholar
  48. Schindler CW, Panlilio LV, Goldberg SR (2002) Second-order schedules of drug self-administration in animals. Psychopharmacology (Berl) 163:327–344CrossRefGoogle Scholar
  49. Sloviter RS, Connor JD, Damiano BP, Drust EG (1980) para-Halogenated phenethylamines: similar serotonergic effects in rats by different mechanisms. Pharmacol Biochem Behav 13:283–286PubMedCrossRefGoogle Scholar
  50. Tariot PN, Goldstein B, Podgorski CA, Cox C, Frambes N (1998) Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type. Am J Geriatr Psychiatry 6:145–154PubMedGoogle Scholar
  51. Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30:666–672PubMedCrossRefGoogle Scholar
  52. Tatton WG, Wadia JS, Ju WY, Chalmers-Redman RM, Tatton NA (1996) (−)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl 48:45–59PubMedGoogle Scholar
  53. Terleckyj IA, Heikkila RE (1992) In vivo and in vitro pharmacologic profile of two new irreversible MAO-B inhibitors: MDL 72,974A and fluorodeprenyl. Ann NY Acad Sci 648:365–367PubMedCrossRefGoogle Scholar
  54. Tidey JW, Bergman J (1998) Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs. J Pharmacol Exp Ther 285:1163–1174PubMedGoogle Scholar
  55. Winger G (1994) Dopamine antagonist effects on behavior maintained by cocaine and alfentanil in rhesus monkeys. Behav Pharmacol 5:141–152PubMedCrossRefGoogle Scholar
  56. Winger GD, Yasar S, Negus SS, Goldberg SR (1994) Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys. Clin Pharmacol Ther 56:774–780PubMedCrossRefGoogle Scholar
  57. Yasar S, Bergman J (1994) Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies. Clin Pharmacol Ther 56:768–773PubMedCrossRefGoogle Scholar
  58. Yasar S, Goldberg SR (2000) The antiparkinsonian agent selegiline (l-Deprenyl) maintains moderate rates of i.v. self-administration responding under second-order schedules in squirrel monkeys but does not attenuate the reinforcing effects of amphetamine. J Psychopharmacol 14:A20Google Scholar
  59. Yasar S, Gaal J, Panlilio LV, Justinova Z, Redhi G, Schindler CW (under review) A comparison of drug-seeking behavior maintained by d-amphetamine, l-deprenyl (selegiline) and d-deprenyl under a second-order schedule in squirrel monkeys. submitted to Psychopharmacology (Berl)Google Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Sevil Yasar
    • 1
    • 2
  • Jozsef Gaal
    • 3
  • Zuzana Justinova
    • 2
  • Jack Bergman
    • 4
  1. 1.Division of Geriatric Medicine and GerontologyJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, Department of Health and Human Services, Intramural Research ProgramNational Institute on Drug Abuse, National Institutes of HealthBaltimoreUSA
  3. 3.MegaPharma LtdBudapestHungary
  4. 4.Department of Psychiatry, Harvard Medical School, ADARCMcLean HospitalBelmontUSA

Personalised recommendations